Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Additional data from 52 evaluable patients in a Phase I/II trial (Trial 005) showed that MGCD0103 plus Vidaza azacitidine
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury